Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Myelodysplastic Syndromes × imetelstat × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Myelodysplastic Syndromes 1

Interventions

Decitabine 3 decitabine and cedazuridine drug combination 2 cedazuridine 2 treosulfan 1 luspatercept 1 ivosidenib 1 imetelstat 1 glasdegib 1 enasidenib 1 GRN163L peptide 1 Daunorubicin 1 Cytarabine 1 Busulfan 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡